Our dataset includes a total of eight biopsies derived from four patients (Fig. 1a) that received a CDK4/6 inhibitor in combination with endocrine therapy, which is a common combination therapy in metastatic HR+ breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.